NASDAQ: VCELVericel Corp Stock
$37.38+0.35 (+0.95%)
Updated Jun 10, 2026
VCEL Price
$37.38
Fair Value Price
$7.76
Market Cap
$1.91B
52 Week Low
$28.95
52 Week High
$44.27
P/E
86.93x
P/B
5.36x
P/S
5.59x
PEG
1.83x
Dividend Yield
N/A
Revenue
$292.09M
Earnings
$21.46M
Gross Margin
74.8%
Operating Margin
7.86%
Profit Margin
7.3%
Debt to Equity
0.36
Operating Cash Flow
$62M
Beta
1.46
Next Earnings
Jul 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A
VCEL Overview
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VCEL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VCEL
Ranked#37 of 462
Ranked#37 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important VCEL news, forecast changes, insider trades & much more!
VCEL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VCEL ($37.38) is overvalued by 381.92% relative to our estimate of its Fair Value price of $7.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VCEL ($37.38) is not significantly undervalued (381.92%) relative to our estimate of its Fair Value price of $7.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VCEL ($37.38) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VCEL due diligence checks available for Premium users.
Valuation
VCEL fair value
Fair Value of VCEL stock based on Discounted Cash Flow (DCF)
Price
$37.38
Fair Value
$7.76
Overvalued by
381.92%
VCEL ($37.38) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VCEL ($37.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VCEL ($37.38) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VCEL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
86.93x
Industry
18.33x
Market
14.77x
VCEL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VCEL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
VCEL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.36x
Industry
4.71x
VCEL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VCEL price to earnings growth (PEG)
For valuing profitable companies with growth potential
VCEL is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
VCEL's financial health
Profit margin
Revenue
$68.4M
Net Income
-$6.3M
Profit Margin
-9.2%
VCEL's Earnings (EBIT) of $22.96M... subscribe to Premium to read more.
Interest Coverage Financials
VCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$485.6M
Liabilities
$129.4M
Debt to equity
0.36
VCEL's short-term assets ($244.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCEL's short-term assets ($244.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCEL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$16.4M
Investing
-$4.2M
Financing
-$3.0M
VCEL's operating cash flow ($61.69M)... subscribe to Premium to read more.
Debt Coverage Financials
VCEL vs Biotech Stocks
Vericel Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.